Monday, August 15, 2011

Intersect sinus treatment gets FDA approval

Intersect ENT Inc. on Monday announced that the U.S. Food and Drug Administration has approved its premarket application for a sinusitis treatment.
Palo Alto-based Intersect focuses on treatment for ear, nose and throat patients.
The company's product, Propel, is an implant that offers controlled drug delivery for chronic sinusitis.

No comments:

Post a Comment